Monoclonal antibody shows promise for treating acute respiratory distress syndrome

Monoclonal antibody shows promise for treating acute respiratory distress syndrome

A recent proof-of-concept study has found that a monoclonal antibody called ALT-100 may offer a much-needed treatment for acute respiratory distress syndrome (ARDS), a life-threatening lung condition that has no FDA-approved pharmacotherapy and carries a nearly 40% mortality rate.

ARDS occurs when an inflammatory cascade triggered by infection or injury leaks fluid into the lungs, crashing blood oxygen levels. An estimated 500,000 people are diagnosed with ARDS annually in the United States, with 2 million cases globally. The condition was a frequent cause of death during the COVID-19 pandemic.

The study, led by Joe G.N. Garcia, M.D., associate vice president for research at UF Health and director of The Center for Inflammation Science and Systems Medicine at The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, found that ALT-100 significantly increased ventilator-free days in ARDS patients, averaging 21 days versus 14 for placebo.

ALT-100 targets extracellular NAMPT, a master regulator of inflammation, putting brakes on excessive immune response without dampening infection-fighting ability. The treatment group also demonstrated reduced inflammatory markers and lower organ failure scores, with a safety profile comparable to placebo.

Garcia's research groups have studied the antibody's therapeutic potential in preclinical models of approximately 20 conditions, including liver fibrosis, pregnancy loss, advanced prostate cancer, heart disease, neonatal necrotizing enterocolitis, and lupus-related vasculitis. "This is a Humira-like drug, targeting the innate immune response, which is why it has profound implications for diseases like cancer, organ fibrosis and so on," he said.

The study carries an important limitation: the small sample size. The research team had aimed to enroll 60 patients, but strict inclusion criteria requiring treatment within six hours of diagnosis caused enrollment delays, and additional funding would have been necessary to recruit more participants.

Beyond the ARDS indication, Garcia has received clearance from the U.S. Food and Drug Administration to study ALT-100 in patients with progressive pulmonary fibrosis, a buildup of scar tissue in the lungs often seen in autoimmune disease and common among ARDS survivors. He now seeks funding for a larger clinical trial to further validate the antibody's efficacy in ARDS.

Looking ahead, Garcia hopes to obtain funding for a larger clinical trial to further validate the efficacy of ALT-100 in ARDS. If successful, this treatment could offer a much-needed option for patients with this devastating condition. As the medical community continues to search for effective treatments for ARDS and other respiratory diseases, the development of monoclonal antibodies like ALT-100 may be an important step forward.